Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Anna Laemmerer"'
Autor:
Jasmin Taubenschmid‐Stowers, Michael Orthofer, Anna Laemmerer, Christian Krauditsch, Marianna Rózsová, Christian Studer, Daniela Lötsch, Johannes Gojo, Lisa Gabler, Matheus Dyczynski, Thomas Efferth, Astrid Hagelkruys, Georg Widhalm, Andreas Peyrl, Sabine Spiegl‐Kreinecker, Dominic Hoepfner, Shan Bian, Walter Berger, Juergen A Knoblich, Ulrich Elling, Moritz Horn, Josef M Penninger
Publikováno v:
EMBO Molecular Medicine, Vol 15, Iss 3, Pp n/a-n/a (2023)
Abstract The natural compound Artemisinin is the most widely used antimalarial drug worldwide. Based on its cytotoxicity, it is also used for anticancer therapy. Artemisinin and its derivates are endoperoxides that damage proteins in eukaryotic cells
Externí odkaz:
https://doaj.org/article/7735106cb6194b64bd51f140f2fd01c5
Autor:
Lisa Gabler, Carola Nadine Jaunecker, Sonja Katz, Sushilla van Schoonhoven, Bernhard Englinger, Christine Pirker, Thomas Mohr, Petra Vician, Mirjana Stojanovic, Valentin Woitzuck, Anna Laemmerer, Dominik Kirchhofer, Lisa Mayr, Mery LaFranca, Friedrich Erhart, Sarah Grissenberger, Andrea Wenninger-Weinzierl, Caterina Sturtzel, Barbara Kiesel, Alexandra Lang, Brigitte Marian, Bettina Grasl-Kraupp, Martin Distel, Julia Schüler, Johannes Gojo, Michael Grusch, Sabine Spiegl-Kreinecker, Daniel J. Donoghue, Daniela Lötsch, Walter Berger
Publikováno v:
Acta Neuropathologica Communications, Vol 10, Iss 1, Pp 1-16 (2022)
Abstract Glioblastoma (GBM) is characterized by a particularly invasive phenotype, supported by oncogenic signals from the fibroblast growth factor (FGF)/ FGF receptor (FGFR) network. However, a possible role of FGFR4 remained elusive so far. Several
Externí odkaz:
https://doaj.org/article/a09b2bdbe34d4252a9676846e4f372c1
Autor:
Bernhard Englinger, Sebastian Kallus, Julia Senkiv, Anna Laemmerer, Patrick Moser, Lisa Gabler, Diana Groza, Christian R. Kowol, Petra Heffeter, Michael Grusch, Walter Berger
Publikováno v:
Cells, Vol 7, Iss 12, p 259 (2018)
Knowledge of intracellular pharmacokinetics of anticancer agents is imperative for understanding drug efficacy as well as intrinsic and acquired cellular resistance mechanisms. However, the factors driving subcellular drug distribution are complex an
Externí odkaz:
https://doaj.org/article/27749548bad24da2a5f58de1701548d9
Autor:
Michael Orthofer, Jasmin Taubenschmid-Stowers, Marianna Rozsova, Anna Laemmerer, Daniela Loetsch, Johannes Gojo, Andreas Peyrl, Walter Berger, Ullrich Elling, Moritz Horn, Josef M. Penninger
Publikováno v:
Cancer Research. 83:3951-3951
Forward genetic screens have revolutionized the field of target discovery, target deconvolution, and target validation, particularly in the cancer field. However, most approaches are limited to the interrogation of non-essential factors and identify
Autor:
Christian R. Kowol, Bernhard Englinger, Dina Baier, Johannes Gojo, Anna Laemmerer, Laura Niederstaetter, Walter Berger, Thomas Mohr, Clemens Röhrl, Gerald Timelthaler, Walter Jäger, Patrick Moser, Christine Pirker, Samuel M. Meier-Menches, Lisa Gabler, Petra Heffeter, Julia Senkiv, Sebastian Kallus, Christopher Gerner
Publikováno v:
International Journal of Cancer
Ponatinib is a small molecule multi‐tyrosine kinase inhibitor clinically approved for anticancer therapy. Molecular mechanisms by which cancer cells develop resistance against ponatinib are currently poorly understood. Likewise, intracellular drug
Autor:
Christian Dorfer, Andreas Peyrl, Karl Roessler, Carola Jaunecker, Christine Pirker, Walter Berger, Sabine Spiegl-Kreinecker, Lisa Mayr, Johannes Gojo, Christine Haberler, Anna Laemmerer, Irene Slavc, Lucia Kastler, Thomas Czech, Dominik Kirchhofer, Daniela Lötsch-Gojo, Amedeo A. Azizi, Lisa Gabler
Publikováno v:
Neuro-Oncology. 23:vi33-vi34
BACKGROUND High-grade gliomas are among the most aggressive brain tumors across all age groups. BRAF is within the most frequently altered genes in pediatric glioma, sometimes connected with telomerase reverse transcriptase (TERT) promoter mutations,
Autor:
Anna Laemmerer, Dominik Kirchhofer, Sibylle Madlener, Daniela Loetsch-Gojo, Carola N Jaunecker, Lisa Gabler, Lisa Mayr, Natalia Stepien, Alicia Baumgartner, Karin Dieckmann, Stefan M Pfister, Marcel Kool, Sonja Krausert, Apurva Gopisetty, Natalie Jäger, Andreas Peyrl, Amedeo A Azizi, Walter Berger, Johannes Gojo
Publikováno v:
Neuro-Oncology. 24:i73-i73
Pediatric high-grade gliomas (pHGG) account for approximately 12% of pediatric brain tumors. Despite advances in molecular diagnosis and identification of discrete molecular subtypes, pHGG are the leading cause of cancer-related death in children. Th
Autor:
Lisa Mayr, Armin S. Guntner, Sibylle Madlener, Maria T. Schmook, Andreas Peyrl, Amedeo A. Azizi, Karin Dieckmann, Dominik Reisinger, Natalia M. Stepien, Kathrin Schramm, Anna Laemmerer, David T. W. Jones, Jonas Ecker, Felix Sahm, Till Milde, Kristian W. Pajtler, Mirjam Blattner-Johnson, Miroslav Strbac, Christian Dorfer, Thomas Czech, Dominik Kirchhofer, Lisa Gabler, Walter Berger, Christine Haberler, Leonhard Müllauer, Wolfgang Buchberger, Irene Slavc, Daniela Lötsch-Gojo, Johannes Gojo
Publikováno v:
Journal of Personalized Medicine
Volume 10
Issue 4
Journal of Personalized Medicine, Vol 10, Iss 290, p 290 (2020)
Volume 10
Issue 4
Journal of Personalized Medicine, Vol 10, Iss 290, p 290 (2020)
Targeting oncogenic fusion-genes in pediatric high-grade gliomas (pHGG) with entrectinib has emerged as a highly promising therapeutic approach. Despite ongoing clinical studies, to date, no reports on the treatment of cerebrospinal fluid (CSF) disse
Autor:
Johannes M. Reisecker, Irene Slavc, Sibylle Madlener, Daniela Loetsch-Gojo, Lisa Gabler, Carola Jaunecker, Anna Schrempf, Johannes Gojo, Dominik Kirchhofer, Anna Laemmerer, Walter Berger, Lisa Mayr, Petra Vician, Joanna I. Loizou
Publikováno v:
Neuro Oncol
BACKGROUND Central nervous system (CNS) tumors are the second most common childhood cancer. Despite innovations in surgery and chemo-/radiotherapy, CNS tumors remain the major cause of cancer-related death in children. Previous sequencing analyses in
Autor:
Bernhard Englinger, Bernhard K. Keppler, Petra Heffeter, Julia Senkiv, Sebastian Kallus, Christian R. Kowol, Walter Berger, Anna Laemmerer
Publikováno v:
Nanomedicine
Fibroblast growth factor receptor (FGFR) inhibitors like ponatinib and nintedanib are clinically approved for defined cancer patient cohorts but often exert dose-limiting adverse effects. Hence, we encapsulated the FGFR inhibitors ponatinib, PD173074